Search results for "ANTIRETROVIRAL THERAPY"

showing 10 items of 79 documents

Association of Non-Invasive Markers of Liver Fibrosis with HCV Coinfection and Antiretroviral Therapy in Patients with HIV

2019

Abstract The aim of this study was to assess the main effects and interaction between viral hepatitis C (HCV) coinfection and antiretroviral therapy (ART) by using a nonparametric ANOVA on direct and indirect markers of liver fibrosis in HIV-infected patients. The sample included 178 HIV patients aged from 23 to 65 (36% females). The following parameters were determined in blood of patients: hyaluronic acid, pro-matrix metalloproteinase-1, alanine aminotransferase, aspartate aminotransferase, and platelet count. The FIB-4 index was also calculated. The nonparametric ANOVA revealed no significant interaction between HCV coinfection and ART. This provides evidence for an independent contribut…

0301 basic medicinemedicine.medical_specialtyfib-4Liver fibrosisScienceHuman immunodeficiency virus (HIV)medicine.disease_causeGastroenterologypro-mmp-103 medical and health sciences0302 clinical medicineInternal medicinehyaluronic acidmedicinePlateletliver fibrosisMultidisciplinaryaltNon invasiveQmedicine.disease030112 virologyAntiretroviral therapyCoinfection030211 gastroenterology & hepatologyAnalysis of variancenonparametric anovaViral hepatitisastProceedings of the Latvian Academy of Sciences. Section B, Natural Sciences
researchProduct

Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study

2021

Background. High-resolution estimates of HIV burden across space and time provide an important tool for tracking and monitoring the progress of prevention and control efforts and assist with improving the precision and efficiency of targeting efforts. We aimed to assess HIV incidence and HIV mortality for all second-level administrative units across sub-Saharan Africa. Methods. In this modelling study, we developed a framework that used the geographically specific HIV prevalence data collected in seroprevalence surveys and antenatal care clinics to train a model that estimates HIV incidence and mortality among individuals aged 15–49 years. We used a model-based geostatistical framework to e…

0301 basic medicinesub-Saharan AfricaMaleHIV AntibodieEpidemiologyHIV incidencesHIV Infectionsmortality rateHIV AntibodiesModelling studyHuman immunodeficiency virus prevalence0302 clinical medicineAfrica NorthernRA0421Seroepidemiologic StudiesMedicineNorthernHIV Infection030212 general & internal medicineYoung adult10. No inequalityuncertaintyMozambique11 Medical and Health SciencesHIV mortalityMortality rateIncidence (epidemiology)Incidence1. No povertyHiv incidencearticleMauritaniaHuman immunodeficiency virus infected patientArticlestrackingMiddle Agedhealth care planning3. Good healthPeer reviewLesothoAIDSInfectious DiseasesQR180A990 Medicine and Dentistry not elsewhere classifiedFemaleprenatal careanti human immunodeficiency virus agentseroepidemiologyHumanAdultAdolescentAnti-HIV AgentsImmunologyantiretroviral therapyUnit (housing)03 medical and health sciencesYoung AdultbloodHuman immunodeficiency virus infectionVirologySeroprevalenceHumanshumanDeveloping CountriesEstimationAcquired Immunodeficiency SyndromeSubnational mappingsbusiness.industrySeroepidemiologic StudieHIVAnti-HIV AgentPREVENTION030112 virologymortalitymonitoring3121 General medicine internal medicine and other clinical medicineHuman immunodeficiency virus antibodyAfricabusinessHIV incidence ; HIV mortality ; Subnational mapping ; Sub-Saharan Africa ; Local burden of disease ; Public healthDemography
researchProduct

HIV infection with viro-immunological dissociation in a patient with polycystic kidney disease: Candidate for transplantation?

2016

Highlights • Autosomal dominant polycystic kidney disease is the most common among inherited cystic kidney diseases. • Patients with HIV infection are at risk of developing acute kidney injury and chronic kidney disease. • We provide the first report of HIV infection in a patient with polycystic kidney disease. • Lymphopenia should not contraindicate kidney transplantation in patients with HIV infection.

030232 urology & nephrologyHuman immunodeficiency virus (HIV)Case ReportViro-immunological dissociationmedicine.disease_causeVirological response03 medical and health sciences0302 clinical medicinePolycystic kidney diseaseLymphopeniaPolycystic kidney diseaseMedicine030212 general & internal medicineStage (cooking)Kidney transplantationTransplantationurogenital systembusiness.industryHIV; Lymphopenia; Polycystic kidney disease; Transplantation; Viro-immunological dissociation; Infectious Diseasesvirus diseasesHIVmedicine.diseaseAntiretroviral therapyTransplantationInfectious DiseasesImmunologybusinessIDCases
researchProduct

Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patien…

2012

Objective To investigate the relationship between response to antiretroviral therapy (ART), alcohol use and occurrence of a major coronary or other arterial disease event (CADE) in HIV-infected individuals. Design A cohort study. A Cox model was used to identify the correlates of a first occurrence of a major CADE. Setting The French ANRS CO8 APROCO-COPILOTE cohort was set up in 1997 to study clinical progression and patient-reported outcomes (PRO) after initiating a protease inhibitor-containing ART. Clinical data were retrieved from medical records. Self-administered questionnaires collected data on PRO and behaviours, including alcohol use. Participants Metabolic data were only available…

1683Pathologymedicine.medical_specialtyArterial disease03 medical and health sciences0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)Internal medicinemedicineHiv infected patients1506030212 general & internal medicine17060303 health sciences030306 microbiologyProportional hazards modelbusiness.industryResearchGeneral Medicinemedicine.diseaseAntiretroviral therapy3. Good healthInfectious DiseasesCohort1714businessAlcohol consumptionCohort studyBMJ Open
researchProduct

MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection.

2005

Summary Matrix metalloproteinase-7 (MMP-7) generates soluble Fas Ligand (FasL), which is involved in the apoptotic loss of CD4+ T cells during HIV infection. We evaluated whether two polymorphisms in MMP-7 promoter could influence CD4+ recover in response to antiretroviral therapy, and found that these polymorphisms are ineffective.

AdultCD4-Positive T-LymphocytesMaleImmunologyHuman immunodeficiency virus (HIV)HIV InfectionsMatrix metalloproteinasemedicine.disease_causeMMP-7; Fas ligand; CD4T cells; HIV infectionFas ligandPlasma viral loadGeneticsHumansMedicineMolecular BiologyGenetics (clinical)Polymorphism Geneticbusiness.industryMetalloendopeptidasesGeneral MedicineMiddle AgedViral LoadAntiretroviral therapySoluble fas ligandCD4 Lymphocyte CountAnti-Retroviral AgentsApoptosisMatrix Metalloproteinase 7ImmunologyHIV-1business
researchProduct

Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretrovira…

2015

OBJECTIVE We explored the impact of lifelong cumulative HIV viremia on immunological recovery during antiretroviral therapy, according to the timing of treatment initiation. METHODS We estimated lifelong cumulative HIV viremia in patients followed in the ANRS PRIMO cohort since primary infection, including 244 patients who started treatment during PHI and had at least one treatment interruption, and 218 patients who started treatment later but with no interruptions. The impact of cumulative viremia on current immunological status was analysed using linear and logistic regression models. RESULTS At the last visit on treatment, median CD4 cell count was 645 cells/μl in the early/intermittent …

AdultCD4-Positive T-LymphocytesMalePercentilemedicine.medical_specialtyTime FactorsImmunologyCD4-CD8 RatioHuman immunodeficiency virus (HIV)CD4-CD8 RatioHIV InfectionsViremiaCD8-Positive T-Lymphocytesmedicine.disease_causeLogistic regressionMedication AdherenceCohort StudiesAntiretroviral Therapy Highly ActiveInternal medicineSecondary PreventionmedicineHumansImmunology and AllergyLongitudinal StudiesProspective StudiesViremiaCd4 cell countbusiness.industrymedicine.diseaseAntiretroviral therapyCD4 Lymphocyte CountInfectious DiseasesAnti-Retroviral AgentsCohortImmunologyFemalebusinessAIDS
researchProduct

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease in…

2011

Abstract Background Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce. Methods Subjects with virological success on first-PI-regimens who switched to NNRTI therapy (NNRTI group) or to nucleoside reverse transcriptase (NRTI)-only (NRTI group) were studied. The effect of the switch on the ongoing CD4+ trend was assessed by two-phase linear regression (TPLR), allowing us to evaluate whether a change in the CD4+ trend (hinge) occurred and the time of its occurrence. Furthermore, we described the evolution of the frequencies in CD4-count classes across four relevant time-points (baseline, before and immediately after…

AdultCD4-Positive T-LymphocytesMalemedicine.medical_treatmentProtease InhibitorHuman immunodeficiency virus (HIV)CD4+ T-cellHIV InfectionsBiologymedicine.disease_causeSettore MED/17 - MALATTIE INFETTIVENucleoside Reverse Transcriptase InhibitorTimelcsh:Infectious and parasitic diseasesZidovudineRetrospective Studieimmune system diseasesAntiretroviral Therapy Highly ActivemedicineHumansProtease inhibitor (pharmacology)HIV InfectionProtease Inhibitorslcsh:RC109-216Retrospective StudiesHIV; CD4+ T-cellProteaseCd4 t cellDrug SubstitutionBackground dataHIVvirus diseasesMiddle AgedVirologyHIV; AIDS; CD4; NRTIReverse Transcriptase InhibitorCD4 Lymphocyte CountInfectious DiseasesCD4-Positive T-LymphocyteReverse Transcriptase InhibitorsRitonavirFemaleAdult; Antiretroviral Therapy Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; HIV Infections; Humans; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Time; Drug Substitution; Infectious Diseasesmedicine.drugHumanResearch Article
researchProduct

Transient elastography: A non-invasive tool for assessing liver fibrosis in HIV/HCV patients

2010

AIM: To assess the prevalence of advanced liver fibrosis (ALF) in human immunodeficiency virus (HIV), hepatitis C virus (HCV) and HIV/HCV patients using transient elastography, and to identify factors associated with ALF. METHODS: Between September 2008 and October 2009, 71 HIV mono-infected, 57 HIV/HCV co-infected and 53 HCV mono-infected patients on regular follow-up at our Center were enrolled in this study. Alcohol intake, the main parameters of liver function, presence of HCV-RNA, HIV-RNA, duration of highly active anti-retroviral therapy (HAART) and CD4 cell count were recorded. ALF was defined as liver stiffness (LS) ≥ 9.5 kPa. To estimate liver fibrosis (LF) a further 2 reliable bio…

AdultLiver CirrhosisMalemedicine.medical_specialtyTransient elastographyCirrhosisBrief ArticlevirusesHepacivirusLiver fibrosisHepatitis C virusFibrosis evaluationHIV InfectionsComorbidityHepacivirusmedicine.disease_causeGastroenterologyHuman immunodeficiency virus infectionAntiretroviral Therapy Highly ActiveInternal medicinemedicineHumansAspartate Aminotransferasesbiologybusiness.industrydigestive oral and skin physiologyGastroenterologyHIVLiver fibrosivirus diseasesGeneral MedicineHepatitis CMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CComorbiditydigestive system diseasesAspartate aminotransferase platelet ratio indexLiverImmunologyElasticity Imaging TechniquesRNA ViralHepatitis C virus infectionFIB-4 testLiver functionTransient elastographybusinessWorld Journal of Gastroenterology
researchProduct

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 …

2020

Our aim was to evaluate the association between recent eGFR values and risk of switching from TDF to TAF or dual therapy (DT) in real life. HIV-positive patients achieving HIV-RNA ≤50 copies/mL for the first time after starting a TDF-based regimen were included. Kaplan–Meier (KM) curves and Cox regression models were used to estimate the time from TDF to switch to TAF or DT. 1486 participants were included: median (IQR) age 36 (30–42) years; baseline CKD-EPI eGFR 99.92 (86.47–111.4) mL/min/1.73m2. We observed a consistently higher proportion of people with HIV-RNA ≤50 copies/mL who switched from TDF to TAF rather than to DT. By competing risk analysis, at 2 years from baseline, the probabil…

AdultMale0301 basic medicineMicrobiology (medical)Dual therapymedicine.medical_specialtyTenofovirAnti-HIV Agents030106 microbiologyUrologyRenal functionTenofovir alafenamide03 medical and health sciences0302 clinical medicineHiv infectedeGFRmedicineHumansPharmacology (medical)Prospective StudiesTenofovir alafenamide030212 general & internal medicineDual therapyTenofovirAcquired Immunodeficiency SyndromeAlanineDrug SubstitutionProportional hazards modelbusiness.industryAdenineHIVGeneral MedicineViral LoadAntiretroviral therapyRegimenInfectious DiseasesHIV-1Drug Therapy CombinationFemaleTenofovir disoproxil fumarate.businessViral loadGlomerular Filtration Ratemedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Vitamin D supplementation, bone turnover, and inflammation in HIV-infected patients

2018

IF 1.307 (2017); International audience; ObjectiveTo assess whether vitamin D supplementation could be associated with a modification of inflammatory markers and bone turnover in HIV-1-infected patients.Patients and methodsPatients who participated in an initial survey in 2010 and who were followed in the same department were included in a new study in 2012. Between 2010 and 2012, vitamin D supplementation was offered to patients presenting with hypovitaminosis D as per appropriate guidelines. Clinical examinations were performed, and fasting blood samples were taken for inflammation and bone marker evaluations.ResultsOf the 263 patients who participated in the 2010 study, 198 were included…

AdultMale0301 basic medicinemedicine.medical_specialtyHypovitaminose DHIV InfectionsInflammationGastroenterologyBone remodeling03 medical and health sciences0302 clinical medicineHypovitaminosisN-terminal telopeptideTraitement antirétroviral[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicinemedicineVitamin D and neurologyHumansHiv infected patientsLongitudinal StudiesProspective Studies030212 general & internal medicineVitamin DInflammationVitamin d supplementationbusiness.industryHIVHypovitaminosis DVIHMiddle AgedVitamin D Deficiency16. Peace & justice030112 virologyAntiretroviral therapy3. Good healthInfectious DiseasesDietary SupplementsVitamine DFemaleBone Remodelingmedicine.symptombusinessBone markerMédecine et Maladies Infectieuses
researchProduct